Abstract Glutathione peroxidase 1 (GPX1) is a ubiquitously expressed selenium-dependent enzyme that protects cells against oxidative damage by reducing hydrogen peroxide and a wide range of organic peroxides. Some epidemiological studies have correlated low GPX activity or particular GPX1 polymorphisms with enhanced risk of cancer, although these correlations have not been consistently observed in all populations. Therefore, we conducted the present study to evaluate the possible association of GPX1 Pro198Leu polymorphism and erythrocyte GPX activity with the risk of developing prostate cancer and to clarify whether erythrocyte GPX activity levels were correlated with the GPX1 Pro198Leu genotype in the Macedonian population. The GPX1 Pro198Leu genotype was determined in 82 prostate cancer cases and 123 control individuals. We found an overall protective effect of the variant Leu allele of the GPX1 polymorphism on the prostate cancer risk. Heterozygous carriers of the variant Leu allele had a significantly lower risk of prostate cancer compared with homozygous wild-type individuals (OR, 0.38; 95% CI, 0.20-0.75; P = 0.004). Erythrocyte GPX activity was analyzed in 73 cases and 91 controls. The erythrocyte GPX activity in the cancer group was lower than in the healthy controls. Additionally, we compared the erythrocyte GPX activity in the control group of 90 subjects and found no significant differences by genotype. These findings suggest that individual susceptibility of prostate cancer may be modulated by GPX1 polymorphism and that the combination of genetic factors involved in oxidative response with environmental carcinogens may play an important role in prostate carcinogenesis.
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Introduction
Prostate cancer continues to be the most frequently diagnosed neoplasm, and the second leading cause of cancer-related mortality in men [1] . It is associated with aging and occurs in a latent or in a clinical form in 30-40% of men by the age of 30-50 years, increasing to 75% in men by the age of 80 years [1, 2] . Oxidative stress is an inevitable consequence of aerobic life, and there is growing evidence that the endogenous generation of toxic products of oxidative stress plays a mayor role in aging and agerelated diseases such as prostate cancer [3] . Reactive oxygen species (ROS) are generated by regular metabolic process in vivo and can initiate a cascade of free-radical formation and damage to macromolecules [4] . Endogenous defenses against reactive oxygen species include antioxidant enzymes such as: glutathione peroxidase (GPX), catalase (CAT), and superoxide dismutase (SOD) [5] . Lower levels of essential antioxidants in the circulation have been found to be associated with an increased risk of cancer [6] [7] [8] [9] .
Glutathione peroxidase is a selenium-dependent enzyme that is ubiquitously expressed and protects cells against oxidative damage by reducing hydrogen peroxide and a wide range of organic peroxides with reduced glutathione [10] . The cytosolic form of glutathione peroxidase 1 (GPX1) belongs to a family of selenium-dependent peroxidases that include cytosolic GPX2 [11] , plasma-based GPX3 [12] , and phospholipid hydroperoxidase GPX4 [13] . GPX1 knockout mice have a normal phenotype, but are highly sensitive to oxidative stressors [14] . The GPX1 gene is located at chromosome 3p21. A genetic polymorphism encodes for either proline (Pro) or leucine (Leu) at codon 198 of human GPX1 (reference SNP cluster identifier number: 1050450) [15, 16] .
Studies that examine the possible association of the GPX1 Pro198Leu polymorphism and cancer have given contradictory results. Some studies reported that the Leu allele was associated with an increased risk of breast cancer [9, 17] , while others could not confirm these results [18, 19] . No association was found with risk of basal cell carcinoma [20] or colorectal cancer [21] . However, most recently studies reported that the variant Leu allele was associated with a significant lower risk for lung cancer [22, 23] .
The identity of the amino acid at codon 198 (proline or leucine) might have functional consequences with regard to the level of enzyme activity in response to increasing levels of selenium provided to cells in culture [17] . The GPX1 Leu genotype has been associated with lower enzyme activity in one study [9] but not in another [24] .
We conducted the present study to evaluate the possible association of the GPX1 Pro198Leu polymorphism and erythrocyte GPX activity with the risk of developing prostate cancer and to clarify whether erythrocyte GPX activity levels were correlated with the GPX1 Pro198Leu genotype.
Materials and methods

Study population
A total of 82 men diagnosed with primary, histologically confirmed prostate cancer (mean age: 69.55 ± 7.56 years; range: 52-86 years), and 123 controls (mean age: 69.28 ± 7.68 years; range: 50-85 years) were enrolled in the study. All patients were recruited from the outpatient departments of the University Clinics of Urology and Nephrology in Skopje between May 2006 and November 2007. Agematched male subjects admitted to the same hospital during the same period of time, with histologically confirmed non-neoplastic diseases, served as controls. Written informed consent was obtained from all participants of the study before collection of blood specimens. A questionnaire was used to elicit detailed information on demographic and clinical variables, smoking, prior disease history, and family history of cancer. None of the participants were taking antioxidant or vitamin supplements, including selenium, at the time of the study. None of the subjects had a drinking habit, and none of them had consumed any alcohol, starting at least 48 h prior to blood collection.
All tumors were diagnosed histologically with specimens obtained at biopsy or surgical resection by a senior pathologist at the Institute of Pathology, Medical Faculty, Skopje. The cancerous tissue from prostate biopsies and prostatectomy specimens was graded according to the Gleason histopathological grading system, based on the architecture of the glandular tissue, glandular differentiation, and cellular and nuclear appearance [25] .
Genotyping of GPX1 polymorphism Blood samples were drawn from the antecubital vein following an overnight fast, into tubes containing EDTA. Erythrocyte lysates were stored at -70°C until assayed, while genomic DNA was extracted from peripheral blood lymphocytes following standard proteinase K, phenol/chloroform extraction/ ethanol precipitation procedure [26] .
The GPX1 Pro198Leu polymorphism was genotyped by real-time polymerase chain reaction (PCR) as described by Ratnasinghe et al. [27] . Briefly, oligonucleotide sequences for primers and probes to detect the C to T polymorphism in codon 198 were: PCR forward TGTGCCCCTACGCAGGTACA, PCR reverse: CCCCCGAGACAGCAGCA, C allele probe VIC CTGTCT CAAGGGCCCAGCTGTGC TAMRA and T allele probe FAM CTGTCTCAAGGGCTCAGCTGT GCCT TAMRA . Reactions (10ll) contained approximately 20 ng genomic DNA isolated from whole blood, 29 TaqMan Master Mix, dual labeled probes (100 nM each), and PCR primers (900 nM each). PCR reaction was run on a Mx3005P
(TM) QPCR System (Stratagene) under the following conditions: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 62°C for 1 min. Genotyping was repeated on a random 10% samples and results were identical to the original run.
Erythrocyte GPX activity GPX activity was measured in erythrocyte lysates as previously described by Aydin et al. [28] . Briefly, a reaction mixture containing 1 mmol/l Na 2 EDTA, 2 mmol/l reduced glutathione, 0.2 mmol/l NADPH, 4 mmol/l sodium azide, and 1000 U glutathione reductase in 50 mmol/l TRIS buffer (pH 7.6) was prepared. Twenty microliters of erythrocyte lysate and 980 ll of the reaction mixture were mixed and incubated for 5 min at 37°C. The reaction was initiated by adding 8.8 mmol/l hydrogen peroxide, and the decrease of absorbance was recorded at 340 nm for 3 min. GPX activity was expressed in U/ml.
Statistical analysis
Demographic information stratified by case-control status was tabulated as a mean ± standard deviation for continuous variables and a number (and percentage) for categorical variables. Pearson's v 2 test was used to assess group differences on categorical variables and a two-sample t-test was used to assess group differences for continuous variables. Comparison of the erythrocyte GPX activity between cases and controls was carried out by a two-sample t-test. A Kruskal-Wallis nonparametric analysis of variance (ANOVA) test was used to assess whether mean concentration of erythrocyte GPX activities varied by genotype among the controls. Allele and genotype frequencies of cases and controls were compared with values predicted by Hardy-Weinberg's equilibrium using the v 2 test. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate associations between GPX1 genotypes and prostate risk. Calculation for the case-control study was performed using the DeFinetti computer program http://ihg.gsf. de/cgi-bin/hw/hwa1.pl. In all cases P values B 0.05 were considered statistically significant.
Additionally, study subjects were stratified according to age (based on age at diagnosis for cases, or age at selection for controls) to evaluate the relationship of the GPX1 polymorphism with early-onset prostate cancer.
The association of the GPX1 polymorphism and disease status was studied with refitted models for nonaggressive and aggressive prostate cancer, respectively. Men diagnosed with high-grade cancer (Gleason score of 7-10) were categorized as having aggressive disease; those diagnosed with low-grade prostate cancer (Gleason score 2-6) were categorized as having nonaggressive disease.
For all analyses, we first examined the association of GPX1 Pro/Leu and Leu/Leu genotypes, using Pro/Pro as a reference. Next, as a result of the lack of complete information on the functional significance of the GPX1 Pro198Leu polymorphism, we analyzed the data under the assumption of both a dominant (grouping heterozygous with homozygous rare allele) and recessive model (grouping heterozygous with wild type).
Overall, we had 82 cases and 123 controls to examine the association between GPX1 polymorphism and risk of prostate cancer. According to the data availability, the sample sizes were reduced for the interaction models: 75 cases and 117 controls were analyzed to evaluate the association with age at diagnosis, whereas the analysis of disease status interaction included 72 cases. Erythrocyte GPX activity was analyzed in 73 cases and 91 controls, while genotype-activity relationship was studied in 67 cases and 90 control subjects. Table 1 shows a case-control comparison of selected baseline subject characteristics. As expected, total PSA levels were significantly different in cases compared with controls. Age and smoking status were not different in prostate cancer cases compared to controls.
Results
Subject characteristics
Erythrocyte GPX activity
As evident from the results shown in Table 2 we found significantly lower erythrocyte GPX activity in the prostate cancer patients group versus controls (P \ 0.001).
GPX1 polymorphism and prostate cancer risk Table 3 shows the association between GPX1 genotype and prostate cancer risk. The genotype distribution of GPX1 Pro198Leu was in Hardy-Weinberg equilibrium among the controls. The frequencies of the variant Leu allele were 23.8% and 34.6% in cases and control individuals, respectively. Genotype frequencies were 65.9% (Pro/Pro), 20.7% (Pro/Leu), and 13.4% (Leu/ Leu) for cases, and the respective frequencies were 46.3%, 38.2%, and 15.4% for control individuals. As evident from the comparison of allele frequency, the variant Leu allele was associated with a lower risk of prostate cancer than the Pro allele (OR, 0.60; 95% CI, 0.38-0.92; P = 0.020). Heterozygous (Pro/Leu) genotype had a significant 62% lower risk of prostate cancer (OR, 0.38; 95% CI, 0.20-0.75; P = 0.004) than homozygous wild type (Pro/Pro). Accordingly, carriers of at least one variant allele (Pro/Leu or Leu/Leu genotype) had 55% lower risk of prostate cancer (OR, 0.45; 95% CI, 0.25-0.80; P = 0.006) than homozygous carriers of the wild-type Pro allele.
GPX1 polymorphism and age at diagnosis of prostate cancer
The relation between the GPX1 polymorphism and prostate cancer risk among the cases and controls stratified by age at diagnosis (for cases) and age at selection (for controls) is shown in Table 4 . In the older age group, individuals with the heterozygous (Pro/Leu) genotype were at significantly lower risk for prostate cancer compared to those with the homozygous wild type (Pro/Pro) (OR, 0.30; 95% CI, 0.12-0.72; P = 0.006). Furthermore, the carriers of at least one variant Leu allele (Pro/Leu or Leu/Leu) had 53% lower risk than homozygous carriers of the Pro allele (OR, 0.40; 95% CI, 0.19-0.82; P = 0.011). Overall, in this older age subgroup, the variant Leu allele was associated with 44% lower risk of prostate cancer than the Pro allele (OR, 0.56; 95% CI, 0.32-0.98; P = 0.041).
GPX1 polymorphism, aggressive versus nonaggressive prostate cancer
No significant difference was found in GPX1 genotype or allele frequency between subgroups of cases divided by disease status (aggressive versus nonaggressive prostate cancer) ( Table 5) . 
\0.001
a P from a two-sample t-test GPX1 genotype and GPX activity correlation Table 6 shows GPX1 genotype and corresponding GPX erythrocyte activity levels. When measured in erythrocytes, the GPX activity was not significantly different between the groups of individuals representing the Pro/Pro, Pro/Leu, and Leu/Leu genetic variants, both in cases and in control individuals. 
Discussion
In the present study, we found an overall protective effect of the Leu allele of the GPX1 polymorphism on the risk for prostate cancer. Heterozygous carriers of the variant Leu allele had a significantly lower risk of prostate cancer compared with homozygous wild-type individuals. This association is evident in the subgroup of men older than 65 years, whereas no significant association was found in the subgroup of younger men. Furthermore, GPX1 genotype was not associated with the disease status of the prostate cancer.
To our knowledge, to date, only one study has investigated the relationship of GPX1 Pro198Leu and prostate cancer risk: Choi et al. [29] , who failed to find associations between GPX1 Pro198Leu polymorphism and prostate cancer risk among men with a history of smoking and/or asbestos exposure. Further analyses stratified by factors related to environmental oxidative stress exposures did not modify associations [29] .
The finding in our study appear to be compatible with the data obtained in studies of lung cancer [22, 23] , suggesting that the GPX1 Leu allele may be a protective allele for these types of human cancer.
Furthermore, in our study we found lower erythrocyte GPX activity in the cancer group than in the healthy controls. These data confirmed our results obtained in a Turkish population published in a previous study in which we reported that lower GPX activity was associated with prostate cancer [6] . There are variable reports on the activity of this enzyme in prostate cancer. Jung et al. [30] found no differences in the antioxidant enzymatic activities of prostatic epithelial cell cultures between benign and malign tissue. In other studies, malignant epithelial cells in prostatic adenocarcinoma have been found to express lower levels of antioxidant enzymes than do benign prostatic epithelium [31] or almost no superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase (CAT) enzyme [32] . With the lowered GPX activity in the cancer group, an accumulation of H 2 O 2 might occur, resulting in higher production of OH . radicals. This highly reactive oxidant molecule binds and oxidizes DNA, lipids, and proteins, and it reacts with structures in its close neighborhood. Any oxidative lesion that is not repaired can lead to mutations, increasing the risk of carcinogenesis [3] .
Additionally, we determined the erythrocyte GPX activity in 67 cases and 90 control subjects and found no significant difference by genotype. Our results agree with a previous study that investigated the genotype-activity relationship of the GPX1 polymorphism and reported no difference in activity by genotype [24] . On the contrary, the results of RavnHaren et al. [9] indicated that the GPX1 variant has 10% lower activity than the wild-type enzyme. Our findings might seem somewhat contradictory: the effect of the GPX1 genotype on prostate cancer risk would be expected if GPX enzyme activity differs between the genotypes, such that a low-activity allele would be associated with a relatively high risk for prostate cancer due to less efficient prevention of oxidative damage to DNA caused by oxygen radicals. Thus, we must consider other explanations than the GPX enzyme activity. A possible cause for the potentially protective effect of the Leu allele of the GPX1 polymorphism might be a co-segregating functional polymorphism in another gene in the same region of the genome and not the GPX1 polymorphism itself. For example, the RhoA gene that encodes RhoA GTPase, a well-known mediator in signal transduction, is located next to the GPX1 gene [33] . It was reported that uncontrolled activation, due to overexpression of different members of the Rho family in a variety of tissues, leads to uncontrolled proliferation and invasiveness of human tumors. Co-segregation between the GPX1 and a biological effective polymorphism in another gene near GPX1, such as the RhoA gene, may explain a lower cancer risk in association with the GPX1 Leu genotype [23] .
Additionally, different dietary and lifestyle factors may influence GPX enzyme activity. In a recent human intervention study it was shown that the intake of fruit and vegetables significantly increased the activity of GPX in human erythrocytes [34] and selenium supplementation is well known to increase GPX activity in populations with a low intake of this trace element (\ 40 mg/day) [17, 35] . Alcohol induces lipid peroxidation and has been reported also to decrease erythrocyte GPX activity in some human studies but not in others [9, 23] . The complete story of the GPX1 genotype is probably complex, a situation that has proven true for many or most single-nucleotide polymorphisms.
In conclusion, these findings suggest that reactive oxygen species may play an important role in prostate carcinogenesis, and individual susceptibility of prostate cancer may be modulated by GPX1 polymorphism. The present study showed a significant lower risk of prostate cancer in association with the GPX1 Leu variant allele. However, the decreased risk of the GPX1 variant allele was difficult to interpret since we found no significant difference in erythrocyte GPX activity by genotype. More functional studies of the GPX1 polymorphism and additional polymorphisms in other oxidative stress response genes in large pooled studies will help to clarify their role in carcinogenesis. If confirmed by other studies, these findings could improve the assessment of prostate cancer risk and clinical management in these patients. 
